BMTA has been active in the Israeli market since its founding 10 years ago. Many of the Israeli companies started working with BMTA early in their development and continue to collaborate with BMTA as they commercialize their technologies. “Our long-term presence in the U.S. market, our focus on establishing clinical adoption for innovative technologies in the rapidly changing U.S. and world markets, and our ability to interact with Israeli companies and investors position us in a unique place in the vibrant Israeli market,” stated David Barone, a principal of BMTA and a strong promoter of expanding business relationships between Massachusetts and Israel, “Massachusetts has much to offer to Israeli life science companies and those taking advantage of the available resources often find that local relationships provide significant value.”
Through their collaboration with BMTA, a number of Israeli companies have selected Massachusetts as their base of operation in the U.S. Other companies conducted clinical research in Massachusetts-
“I have been involved through three different Israel-based medtech companies with BMTA, being supported in the development of market strategy, regulatory, reimbursement and other critical elements of our plans to commercialize our new medical technologies. BMTA experience, ability to identify the barriers and support the spectrum of activities that eventually lead to market acceptance, and their ability to effectively work with Israeli companies, is unique", stated Israel Schreiber, CEO of Ornim Medical, and past CEO of ITGI Medical (TASE:ITGI) and Itamar Medical (TASE:Itamar)
BMTA’s collaboration with Israeli companies is further enhanced by other activities that expand collaboration between Massachusetts and Israel. Last month BMTA organized a seminar on recent changes in regulatory and reimbursement environment in the U.S. and their implications for medical device manufacturers. The seminar took place in Tel Aviv, Israel, and was attended by senior executives from 60 Israeli life science companies.
BMTA also played a key role in supporting and organizing the New England - Israel Business Council (NEIBC) Life Sciences Summits in 2010 and 2012, which brought together hundreds of Massachusetts-
About Boston MedTech Advisors, Inc.
BMTA is a consulting and professional services firm supporting commercialization of new medical technologies and helping manufacturers achieve market adoption of new products, technologies and procedures. BMTA has offices in Dedham, MA, Germany and Israel. BMTA activities include market research, regulatory affairs, development of clinical evidence, assessment of reimbursement and economics of products and related procedures, marketing strategy and more. BMTA has consulted and assisted U.S. and offshore medical technology organizations, ranging from start-ups to Fortune 500 companies, as well as investors, tech transfer offices and healthcare providers. Additional information about Boston MedTech Advisors can be found at www.bmtadvisors.com and www.bmtCROgroup.com.
This announcement by Boston MedTech Advisors, Inc. was featured at a Dec. 5 event with Massachusetts Gov. Deval Patrick and Massachusetts and Israeli business leaders in Boston. The event included the release of important findings by the New England-Israel Business Council that describes the multi-billion dollar impact of Israeli-founded companies on Massachusetts and their role as a critical growth engine for the Massachusetts economy. A whitepaper that details the research findings is available at www.neibc.org (http://www.neibc.org).